The following table provides an overview of the latest patents of Aventis Pharma S.a. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2493466Mar 10, 2021Novel Antitumoral Use Of Cabazitaxel13
EP3294285Dec 18, 2019Cabazitaxel And Its Use For Treating Cancer9
EP2678011Jun 26, 2019Antitumoral Combination Comprising Cabazitaxel And Cisplatin1